Successful treatment of an end-stage kidney disease patient presenting with severe Covid-19 disease using enhanced cytokine removal with haemoadsorption therapy in addition to standard management


Endstage renal disease
Cytokine storm
Haemoadsorption therapy



Endstage renal disease patients with severe COVID-19 disease has higher mortality rate as compared to those with no comorbidities. Here we report a case of endstage renal disease patient who was on regular haemodialysis presenting with severe COVID-19 disease and progressed to cytokine storm. In addition to standard management with steroids in view of the hypoxia, this patient received haemoadsorption therapy to aid cytokine removal hence potentially limiting the progression of the acute respiratory distress syndrome and preventing mortality. There are limited data on the use of haemoadsorption in endstage renal disease patients with COVID-19 disease. This patient survived to discharge without the need for supplemental oxygen. In conclusion, combined therapeutic modalities are possible promising treatment for severe COVID-19 infection in endstage renal disease patients.



Iannaccone G, Scacciavillani R, Del Buono MG et al. Weathering the Cytokine Storm in COVID-19:Therapeutic Implications. Cardiorenal Med 2020. DOI:10.1159/000509483

Tang Y, Liu J, Zhang D, Xu Z, Ji J and Wen C (2020) Cytokine Storm in COVID-19:The Current Evidence and Treatment Strategies. Front. Immunol 11:1708. Doi:10.3389/fimmu.2020.01708

Shadvar K et al. Hemoperfusion as a potential treatment for critically ill COVID-19 patients with cytokine storm. Blood Purif 2021;50:405-407.

Vardanjani AE et al. Early Hemoperfusion for Cytokine Removal May Contribute to Prevention of Intubation in Patients Infected with COVID-19. Blood Purif 2021;50:257-260

Ankawi G, Fan W, Montin DP et al. A New Series of Sorbent Devices for Multiple Clinical Purposes:Current Evidence and Future Directions. Blood Purif 2019;47:94-100.

Mao L, Jin H, Wang M et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020, 77, 683.

Orsucci D, Trezzi M, Anichini R et al. Increased creatine kinase may predict a worse COVID-19 outcome. J. Clin. Med 2021, 10, 1734.

Orsucci D. Is creatine kinase associated with outcome in COVID-19? Neuroimmunol Neuroinflammation 2020;7:[Online First].

Horby P, Lim WS, Emberson JR et al. The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with COVID-19. N Engl J Med 2021;384:693-704. DOI:10.1056/NEJMoa2021436

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright (c) 2022 Journal of Clinical and Translational Nephrology